Last edited by Gardadal
Tuesday, May 19, 2020 | History

4 edition of Potential Therapeutic Uses of Interleukin-1 found in the catalog.

Potential Therapeutic Uses of Interleukin-1

Potential Therapeutic Uses of Interleukin-1

  • 355 Want to read
  • 23 Currently reading

Published by Springer .
Written in English

    Subjects:
  • Immunology,
  • Internal Medicine,
  • Pharmacology,
  • Medical / Internal Medicine,
  • Medical / Nursing,
  • Interleukin 1,
  • Interleukin-1,
  • Testing,
  • Therapeutic use

  • Edition Notes

    ContributionsCharles Dinarello (Editor), Ruth Neta (Editor)
    The Physical Object
    FormatPaperback
    Number of Pages148
    ID Numbers
    Open LibraryOL11151985M
    ISBN 100792306031
    ISBN 109780792306030
    OCLC/WorldCa21153242

    The interleukin-1 receptor antagonist (IL1-ra), compared with interleukin-1 beta (IL-1 beta), dominated the secretions from both cell types with a to fold excess respectively. Download Citation | Interleukin-1 and IL-1 receptor antagonist in stroke: mechanisms and potential therapeutics | The IL-1 family comprises two agonists, IL-lα and IL-1β, the products of.

      Septic shock refers to a state of acute circulatory failure that is characterized by persistent arterial hypotension (systolic pressure.   Despite this treatment approach, a number of patients either do not respond or can not tolerate, the above therapies. For this refractory group, small case series and a recent randomized controlled trial, have shown that interleukin-1 inhibition with anakinra is a rapidly-acting, highly efficient, steroid-sparing and safe therapeutic by:

    Title:Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease VOLUME: 14 ISSUE: 4 Author(s):Shinya Ashizuka, Haruhiko Inatsu, Kyoko Inagaki-Ohara, Toshihiro Kita and Kazuo Kitamura Affiliation:Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Kihara, Kiyotake, Miyazaki-city, Miyazaki, , by: At a symposium, in Ann Arbor, MI, two different groups first reported bioactivities known to be interleukin-1 receptor antagonist (IL-1Ra). The dialyzed and concentrated urine of a patient with acute monocytic leukemia, and fever inhibited the effects of IL-1 on induction of PGE 2, and collagenase production by cultured human dermal by:


Share this book
You might also like
Memoirs of an interpreter

Memoirs of an interpreter

Building service-aware networks

Building service-aware networks

Materials Selection Guidelines for Geothermal Energy Utilization Systems

Materials Selection Guidelines for Geothermal Energy Utilization Systems

Mozart, the wonder boy

Mozart, the wonder boy

Articles of association of the New-York Insurance Company.

Articles of association of the New-York Insurance Company.

building trades

building trades

Topology.

Topology.

Beginning English with younger children

Beginning English with younger children

Reorganization of Rural Electrification Administration.

Reorganization of Rural Electrification Administration.

Annual report & accounts (of the) Commission for the New Towns

Annual report & accounts (of the) Commission for the New Towns

The woman who lives in the earth

The woman who lives in the earth

Child mental health

Child mental health

Potential Therapeutic Uses of Interleukin-1 Download PDF EPUB FB2

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases D Hallegua and M Weisman Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CAby:   Effect of combination IL1Ra and methotrexate treatment versus methotrexate alone on ACR 20% response rates after 24 weeks of treatment.

From Cohen S, Hurd E, Cush JJ, et al. Treatment with interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients [abstract].Cited by: Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases D S Hallegua, M H Weisman.

Ann Rheum Dis;– Objective: To review publications relating to the blocking of interleukin 1 (IL1) as a strategy for treat-ing human disease, ranging from rheumatoid arthritis (RA) to Alzheimer’s by: Potential therapeutic uses of interleukin Biotherapy (Dordrecht, Netherlands), 01 Jan1(4): PMID: Share this article Share with email Share with twitter Share with linkedin Share with facebook.

Abstract. Potential Therapeutic Uses of Interleukin-1 book No abstract provided. Similar Articles. Several studies have reported the use of recombinant interleukin 1 receptor antagonist as a therapeutic strategy for rheumatoid arthritis.

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Hallegua DS(1), Weisman MH. Author information: (1)Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CAby: Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease Valor terapéutico potencial de las estrategias dirigidas contra la interleucina 1β en la enfermedad cardiovascular ateroesclerótica.

and discuss other potential targets related to interleukin 1-beta (IL-1β), the proinflammatory Cited by: 2. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases D Hallegua and M Weisman Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CAUSA.

The data presented by Petrasek et al. 10 provide convincing evidence that IL‐1 signaling plays an important role in ethanol‐induced liver injury in mice, suggesting the therapeutic potential of IL‐1 inhibitors for the treatment of ALD.

At present, three IL‐1 inhibitors have been approved for the treatment of several types of inflammatory diseases. 12 These include the IL‐1 receptor Cited by: The data presented by Petrasek et al. 10 provide convincing evidence that IL-1 signaling plays an important role in ethanol-induced liver injury in mice, suggesting the therapeutic potential of IL-1 inhibitors for the treatment of ALD.

At present, three IL-1 inhibitors have been approved for the treatment of several types of inflammatory diseases. 12 These include the IL-1 receptor antagonist Cited by: Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.

By D Hallegua and M Weisman. Abstract. Methods: The National Library of Medicine's PubMed database was searched for articles about pharmaceutical agents that reduce the biological actions of IL1Author: D Hallegua and M Weisman. The genome-wide analyses indicate that interleukin-1 receptor associated kinase 1 (IRAK1) is associated with the susceptibility of SLE in humans.

In the present study, we identified that IRAK1 was overexpressed and hyper-activated in splenic mononuclear cells from -Fas lpr /Nju () mice and peripheral blood mononuclear cells (PBMCs) from SLE by: 6. The potential use of natural inhibitors such as soluble receptors, interleukin-1 receptor antagonists, and anti-cytokine antibodies is detailed.

This interesting book also covers intracellular signaling pathways induced by pro-inflammatory cytokines and the bio-modulatory activity of specific cytokines such as TGF-ß. Chapter 14 - Flavonoids: Potential Therapeutic Agents by Their Antioxidant Capacity. Tumor necrosis factor alpha (TNF-α) and interleukin 1 (IL-1), as mediators of inflammation and immune response, act on the endothelium, increasing the production of cell adhesion molecules and cytokines that lead to cascading signals that cause leucocitary Author: Patricia Hernández-Rodríguez, Ludy Pabón Baquero, Harold Rodríguez Larrota.

Disulfiram exerts significant anticancer activity in. We have increasing pre-clinical evidence that disulfiram, an old and inexpensive drug in continuous use for 6 decades in alcohol aversion. Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis Nádia Pereira Gonçalves, 1, 2 Paulo Vieira, 3 and Maria João Saraiva 1, 2 1 Department of Molecular Neurobiology, Institute for Molecular and Cell Biology, Rua do Campo Alegre, Porto, PortugalCited by: Title:NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease VOLUME: 23 ISSUE: 16 Author(s):Agampodi Promoda Perera, Dale Kunde and Rajaraman Eri* Affiliation:School of Health Sciences, University of Tasmania, Launceston, Launceston TASSchool of Health Sciences, University of Tasmania, Launceston, Launceston TASSchool of Health Cited by: Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease Valor terapéutico potencial de las estrategias dirigidas contra la interleucina 1β en la enfermedad cardiovascular by: 2.

Interleukin-1 (IL-1) is an important mediator of inflammatory disease. The IL-1 family currently consists of two agonists, IL-1α and IL-lβ, and one antagonist, IL-1ra. Each of these molecules Cited by: Interleukin-1 (IL-1) inhibitors potentially have a role as antiinflammatory agents in refractory gout or for patients who are unable to tolerate conventional therapy, such as nonsteroidal.

A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha.

J. Immunol.– ().Cited by: Interleukin-1 (IL-1) antagonists are potent antiinflammatory drugs that bind and block the IL-1 receptor, stopping the inflammatory cascade early on, and have been used successfully in the treatment of severe rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.AbstractThe use of metals in medicine has grown impressively in recent years as a result of greatly advanced understanding of biologically active metal complexes and metal-containing proteins.

One landmark in this area was the introduction of cisplatin and related derivatives as anticancer drugs. As the body of literature continues to expand, it is necessary to inspect sub-classes of this.